Daré Bioscience, Inc.
DARE
$2.04
-$0.04-1.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -194.64% | 173.12% | -103.52% | -95.83% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -194.64% | 173.12% | -103.52% | -95.83% | -- |
| Cost of Revenue | -- | -31.65% | -34.04% | 0.00% | -- |
| Gross Profit | -194.64% | 32.22% | 27.68% | -98.29% | 189.60% |
| SG&A Expenses | -2.87% | -13.53% | -32.45% | -24.31% | -16.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.43% | -23.63% | -21.46% | -49.74% | -17.88% |
| Operating Income | 47.99% | 23.93% | -8.38% | 44.25% | 18.13% |
| Income Before Tax | -131.11% | 35.19% | -8.87% | 43.34% | 247.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.11% | 35.19% | -8.87% | 43.34% | 247.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.11% | 35.19% | -8.87% | 43.34% | 247.35% |
| EBIT | 47.99% | 23.93% | -8.38% | 44.25% | 18.13% |
| EBITDA | 54.14% | 26.43% | -8.47% | 44.30% | 18.22% |
| EPS Basic | -129.50% | 38.02% | 0.95% | 49.63% | 226.13% |
| Normalized Basic EPS | -129.50% | 38.03% | -14.37% | 49.62% | 226.12% |
| EPS Diluted | -129.79% | 38.02% | 1.06% | 49.63% | 224.59% |
| Normalized Diluted EPS | -129.73% | 38.03% | -14.37% | 49.62% | 225.16% |
| Average Basic Shares Outstanding | 5.47% | 4.57% | 9.92% | 12.48% | 16.82% |
| Average Diluted Shares Outstanding | 4.66% | 4.57% | 9.92% | 12.48% | 17.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |